Related by context. All words. (Click for frequent words.) 73 hepatitis C virus 69 chronic hepatitis C 69 HCV 69 hepatitis B virus HBV 67 chronic HCV infection 66 hepatitis C HCV 64 Hepatitis C virus 64 Hepatitis C HCV 64 Hepatitis C virus HCV 61 CCR5 tropic HIV 61 latent tuberculosis infection 61 HCV infection 61 human immunodeficiency virus 60 chronic HCV 60 hepatitis C 60 hepatitis C genotype 60 HBV 60 virus HCV 60 refractory gout 60 protease inhibitor telaprevir 59 virus HCV infection 59 nucleotide analog 59 HBeAg negative 59 investigational hepatitis C 59 Daclizumab 59 telbivudine 59 chronic hepatitis B 59 chronic HBV infection 59 chronic HCV genotype 58 chemotherapy induced neutropenia 58 HCV genotype 1 58 cytomegalovirus CMV 58 FOLOTYN ® 58 CCR5 antagonist 58 diarrhea predominant irritable 58 TMC# [001] 58 Telaprevir 58 e antigen HBeAg 58 ALN TTR 58 humanized monoclonal antibody 58 Amigal 58 virus HCV protease inhibitor 58 hepatitis B HBV 58 nitazoxanide 58 ALN RSV# 58 chronic HBV 57 Telbivudine 57 HCV protease inhibitor 57 Recombinant interferon alpha 57 investigational monoclonal antibody 57 chronic hepatitis C. 57 protein tyrosine phosphatase 1B 57 ALN PCS 57 Hepatitis C Virus HCV 57 oral prodrug 57 JAK inhibitor 57 HCV genotypes 57 posaconazole 57 toenail onychomycosis 57 PEG Interferon lambda 57 LymphoStat B belimumab 57 Alinia 57 lupus nephritis 57 anti CD3 monoclonal 57 BARACLUDE R 57 relapsing remitting multiple sclerosis 57 Viramidine 57 MYDICAR ® 56 BCR ABL inhibitors 56 viral kinetics 56 daptomycin 56 chronic hepatitis B. 56 herpes simplex virus 56 CCR5 receptor antagonist 56 XL# XL# 56 Vicriviroc 56 Sebivo 56 Hepatitis B virus 56 nucleotide analogue 56 HQK 56 Clostridium difficile associated 56 rheumatoid arthritis RA 56 Cethromycin 56 treatment naïve genotype 56 human monoclonal antibody 56 pradefovir 56 NS5b 56 NS#/#A protease 56 HCV polymerase 56 Elvitegravir 56 Tyzeka 56 decompensated liver disease 56 Helicobacter pylori H. pylori 56 immunomodulator 56 NRTI resistance 56 CCR5 mAb 56 HCV genotype 56 noninfectious uveitis 56 nucleoside analogue 56 Radezolid 56 humanized anti 56 huC# DM4 56 S. aureus infections 56 Hepatitis C Virus 56 dacetuzumab 56 HBeAg positive 56 entecavir 55 investigational compounds 55 HCV SPRINT 55 non nucleoside HCV 55 polymerase inhibitor 55 antibody MAb 55 Dacetuzumab 55 Plicera 55 castrate resistant prostate cancer 55 ketolide antibiotic 55 DAS# [001] 55 HBV infection 55 TYZEKA 55 systemic lupus erythematosus SLE 55 treatment naive genotype 55 R5 tropic 55 ACTEMRA TM 55 ALN TTR# 55 CYT# potent vascular disrupting 55 telaprevir VX 55 Genital herpes 55 Alemtuzumab 55 inhibitor RG# 55 HuLuc# 55 posterior uveitis 55 forodesine 55 JAK1 55 HCV infections 55 cIAI 55 Reverset 55 systemic fungal infections 55 methicillin resistant S. aureus 55 otelixizumab 55 Amgen Neulasta R 55 selective modulator 55 radezolid 55 MVA BN R 55 relapsing remitting MS RRMS 55 Epratuzumab 55 Neulasta ® 55 naive HCV genotype 55 recurrent glioblastoma multiforme 55 VIR# 55 DU #b 55 HCV infected 55 null responder 55 REP# 55 RhuDex ® 55 null responder HCV 55 vidofludimus 55 Viread tenofovir disoproxil fumarate 55 CEQ# 55 vaginal candidiasis 55 elotuzumab 55 naive HCV 55 ORENCIA ® 55 Diabetic Macular Edema 55 ceftazidime 55 recurrent genital herpes 55 AmBisome 55 non nucleoside inhibitor 55 OHR/AVR# 55 terlipressin 55 diabetic macular edema DME 55 Chlamydia trachomatis 55 leukemia CLL 55 Natalizumab 55 adalimumab Humira 55 cSSSIs 55 alfa 2a 55 polymerase inhibitors 55 VivaGel TM 55 HCD# [002] 55 Rheumatoid Arthritis RA 54 Elacytarabine 54 Nanobody 54 Boceprevir 54 varicella zoster virus VZV 54 myelofibrosis polycythemia vera 54 Respiratory Syncytial Virus RSV 54 Staphylococcus aureus infections 54 neurogenic orthostatic hypotension 54 investigational integrase inhibitor 54 BARACLUDE ® 54 pegylated interferon alpha 54 ofatumumab 54 HuMax CD4 54 COPEGUS ribavirin 54 celgosivir 54 R roscovitine 54 Aflibercept 54 PNP inhibitor 54 relapsed multiple myeloma 54 Sym# 54 relapsing multiple sclerosis 54 AEG# 54 New Chemical Entities 54 oral JAK1 54 OncoVEX GM CSF 54 MTP inhibitor 54 HCV NS3 protease 54 SEBIVO 54 Epstein Barr virus EBV 54 LymphoStat B TM 54 Factor VIIa 54 LHRH antagonists 54 Pradefovir 54 drug conjugate 54 Golimumab 54 ocrelizumab 54 lenalidomide Revlimid R 54 candidemia 54 LymphoStat B 54 oral ghrelin agonist 54 invasive candidiasis 54 investigational oral hepatitis C 54 multiple myeloma MM 54 AA Amyloidosis 54 clevudine 54 generation NNRTI 54 sJIA 54 Mipomersen 54 small molecule thrombopoietin 54 replicon 54 Actemra tocilizumab 54 diabetic nephropathy 54 Nasdaq MITI biopharmaceutical 54 MyVax R 54 SHPT 54 Potelligent Technology 54 herpes simplex viruses 54 LTBI 54 Phase 2b clinical 54 BCX# 54 CCR9 antagonist 54 post herpetic neuralgia PHN 54 RDEA# 54 dirucotide MBP# 54 Hepatitis B Virus 54 invasive aspergillosis 54 CMV disease 54 solithromycin 54 Triolex 54 human immunodeficiency 54 refractory chronic myeloid 54 bevirimat 54 TNF alpha antagonist 54 HBsAg 54 Herpes Simplex Virus 54 valopicitabine 54 hyperuricemia 54 tyrosine kinase inhibitor TKI 54 Civacir 54 targeting CD# 54 Altastaph 54 Racivir 54 HCV polymerase inhibitor 54 gastrointestinal stromal tumors GIST 54 oritavancin 54 ACZ# 54 relapsed leukemia 54 CMV retinitis 54 ano genital warts 54 Unit Dose Budesonide 54 antisense drug 54 telaprevir 54 CIMZIA TM certolizumab pegol 54 Arcalyst 54 cytomegalovirus infection 54 either acutely decompensated 54 MAXY alpha 54 Blinatumomab 54 CCX# 54 PRT# 54 parasite Trypanosoma cruzi 54 Virulizin ® 54 Archexin 54 adenoviral 54 Fabry Disease 54 nucleoside analogues 54 CD# antibody [001] 54 Sustiva efavirenz 54 Valortim R 54 DEB# 54 Temsirolimus 53 Phase IIa clinical 53 HoFH 53 phase IIb clinical 53 ZFP Therapeutic 53 maribavir 53 MAXY G# 53 therapeutic monoclonal antibodies 53 Hepatitis B Hepatitis C 53 Sapacitabine 53 Personalized Immunotherapy 53 Prodarsan ® 53 postoperative ileus 53 cell lymphoma CTCL 53 pegylated interferons 53 Cetrorelix 53 Talabostat 53 herpes zoster shingles 53 NNRTIs 53 Chronic Hepatitis B 53 immune mediated 53 Chronic Hepatitis C 53 lumiliximab 53 synthetic retinoid 53 evaluating tivozanib 53 Omacetaxine 53 Hepatitis C 53 INS# [001] 53 Virologic 53 HTS assay 53 Panzem R 53 oropharyngeal candidiasis OPC 53 Azixa 53 tafamidis 53 Valopicitabine 53 darunavir Prezista 53 MKC# MT 53 PDE4 inhibitor 53 Aganocide 53 basiliximab 53 pegylated interferon 53 P aeruginosa 53 Dapagliflozin 53 fidaxomicin 53 Clevudine 53 ribavirin therapy 53 relapsed MM 53 proteasome inhibitor 53 leukemia AML 53 epothilone 53 Velcade bortezomib 53 HCV RESPOND 2 53 BRAF mutation 53 Vidofludimus 53 anthrax botulism typhoid 53 EOquin 53 lipohypertrophy 53 Familial Adenomatous Polyposis FAP 53 MYDICAR 53 CTAP# Capsules 53 Chronic hepatitis B 53 TREANDA 53 MEK inhibitor 53 methylnaltrexone 53 Bucindolol 53 Sudhir Agrawal D.Phil 53 Chronic hepatitis C 53 CCR5 inhibitors 53 forodesine hydrochloride 53 hypereosinophilic syndrome 53 IAP inhibitors 53 INCB# [001] 53 discontinued Viread 53 phase IIb study 53 chronic myeloid leukemia CML 53 Amrubicin 53 refractory chronic lymphocytic 53 HIV coinfected 53 Hemopurifier 53 voriconazole 53 integrase inhibitor 53 oral antiviral 53 monoclonal antibody 53 preclinical 53 hepatocellular cancer 53 nucleoside 53 BRIM3 53 IDX# 53 Clostridium difficile infection 53 teduglutide 53 Hedgehog antagonist 53 histone deacetylase HDAC inhibitor 53 pediatric Crohn disease 53 monoclonal antibody mAb 53 trastuzumab DM1 T DM1 53 antisense drugs 53 genotypic resistance 53 Vacc 4x 53 EndoTAG TM -1 53 TTR gene 53 dirucotide 53 panitumumab Vectibix 53 metastatic neuroendocrine tumors 53 coinfection 53 humanized monoclonal 53 sorafenib tablets 53 Acute Radiation Syndrome ARS 53 LEUKINE 53 Enzastaurin 53 XmAb# 53 cetuximab Erbitux R 53 Neisseria gonorrhoeae 53 CD3 monoclonal antibody 53 Traficet EN 53 immunocompetent 53 Liprotamase 53 multidrug resistant 53 HspE7 53 varicella zoster virus 53 HCV protease inhibitors 53 immune modulators 53 lymphoma CTCL 53 Solazed TM 53 NXL# 53 methionine aminopeptidase 53 hepatitis C infection 53 alvespimycin 53 oral Janus kinase 53 overactive bladder OAB 53 VGV 1 53 tigecycline 53 OvaRex ® MAb 53 BENLYSTA TM 53 Locteron 53 agonistic human 53 Phase 2a clinical 53 cilengitide 53 idiopathic pulmonary fibrosis IPF 53 StaphVAX R 53 hepatitis C viral infection 53 recurrent glioma 53 immunocompromised patients 53 Alocrest 53 Syndrome HARS 53 pegloticase 53 Fx #A 53 acetonide FA 53 INSPIRE Trial Phase III 53 TBC# 53 targeted radiotherapeutic 53 prokinetic agent 53 novel VDA molecule 53 oral JAK#/JAK# inhibitor 53 Etravirine 53 XL# [003] 53 T#I [002] 53 Restanza 53 NP2 Enkephalin 53 biodefense countermeasure 53 viral subtypes 53 telaprevir dosed 53 esophageal candidiasis 53 trastuzumab emtansine T DM1 53 selectively inhibit replication 53 Symadex 53 JNJ Q2 53 sustained virologic response 52 HSV2 52 antiviral activity 52 SPRYCEL ® 52 pegylated interferon alfa 2a 52 neuropathic pain metabolic diseases 52 lupus renal disease 52 UPLYSO 52 MyVax ® 52 StaphVAX 52 novel therapeutic antibodies 52 Rilonacept 52 immune modulatory 52 Tß4 52 gastrointestinal stromal tumors 52 zidovudine AZT 52 signal transduction inhibitors 52 ImmunoVEX HSV2 52 Aptivus ® 52 orally bioavailable 52 Duchenne muscular dystrophy DMD 52 Myelodysplastic syndromes MDS 52 Thiovir 52 combination antiretroviral therapy 52 protease inhibitor mutations 52 GRNVAC1 52 onychomycosis 52 ABSSSI 52 thymalfasin 52 CD# monoclonal antibody 52 mertansine 52 TÎ ² 4 52 tyrosine kinase inhibitor 52 Gag polymorphisms 52 OTCBB NVLT biopharmaceutical 52 Proxinium TM 52 humanized monoclonal antibodies 52 ELACYT 52 herpes zoster virus 52 metastatic renal cell carcinoma 52 R#/MEM # 52 Vitaxin 52 vWD 52 mild vasodilator 52 kidney urologic 52 Kaposi sarcoma 52 investigational humanized monoclonal antibody 52 sodium glucose cotransporter 52 CXCR4 52 FLT3 52 JAK2 Inhibitor 52 Naive Patients 52 nucleoside analog 52 ACTEMRA 52 Dalbavancin 52 superficial bladder cancer 52 AA amyloidosis 52 antibiotic resistant bacterial infections 52 Candesartan 52 hypoparathyroidism 52 Ribavirin causes 52 HSV1 52 Amgen Neulasta ® 52 delta isoform 52 gastrointestinal stromal tumor GIST 52 Celgosivir 52 indolent NHL 52 Nitazoxanide 52 cirrhosis liver failure 52 GSK '# 52 CMV infection 52 bardoxolone 52 anti CD# antibody 52 Nexavar ® 52 ribavirin RBV 52 Nasdaq VRTX 52 NOXAFIL 52 INC# 52 Phase Ib clinical 52 psoriatic arthritis PsA 52 Chlamydia pneumoniae 52 REYATAZ R 52 adult chronic ITP 52 phosphatidylserine PS targeting 52 investigational protease inhibitor 52 metastatic carcinoid 52 multi kinase inhibitor 52 acute myelogenous leukemia AML 52 ankylosing spondylitis AS 52 protease inhibitor PI 52 NEUGENE 52 Gilead Viread 52 rFIXFc 52 inhibit replication 52 Lipodystrophy 52 coinfected 52 acyclovir Lauriad R 52 M#V mutation 52 Tavocept 52 XmAb ® 52 cardio renal 52 cytomegalovirus 52 omega interferon 52 TTR amyloidosis 52 Phase #/#a 52 EV# vaccine 52 AzaSite Plus 52 TYGACIL 52 TNF antagonist 52 darapladib 52 C. trachomatis 52 tuberculosis TB 52 isoform selective 52 Denufosol 52 P#X# antagonist 52 HIV HCV coinfected 52 CCR5 tropic 52 STELARA TM 52 riociguat 52 Sprycel dasatinib 52 DermaVir Patch 52 biologic therapy 52 transcriptase inhibitor NNRTI 52 Tarvacin 52 TELINTRA 52 mRCC 52 dasatinib Sprycel ® 52 Gleevec imatinib mesylate 52 T#I mutant 52 Mycograb 52 Acute Myeloid Leukemia AML 52 non nucleoside reverse 52 interferon lambda 52 Rheumatoid arthritis RA 52 belinostat 52 Phase 1a clinical 52 efalizumab 52 oral methylnaltrexone 52 MAGE A3 ASCI 52 heterozygous FH 52 Entry Inhibitor 52 latent TB infection 52 panobinostat 52 Diamyd ® 52 anal HPV 52 purpura ITP 52 modified glutathione analog 52 ATL/TV# 52 ChronVac C R 52 VitiGam 52 danoprevir 52 Lenocta 52 Hsp# Inhibitor 52 iclaprim 52 cutaneous T 52 glucocorticoid induced osteoporosis 52 Myocet 52 eculizumab 52 Arranon 52 primary immunodeficiency PI 52 Riquent 52 metaglidasen 52 idiopathic thrombocytopenic purpura ITP 52 REMOXY R 52 HIV coinfection 52 investigational compound 52 rheumatoid arthritis Crohn disease 52 nucleotide analogs 52 Pegasys plus Copegus 52 PegIFN RBV 52 clade B 52 virus HBV 52 HepC 52 AVEO Pharmaceuticals Inc. 52 IMA# 52 Cimzia ® certolizumab pegol 52 pan HDAC inhibitor 52 Escherichia coli Klebsiella pneumoniae 52 nicotinic alpha 7 52 Pneumocystis pneumonia PCP 52 rilpivirine 52 genotype 1b 52 peginterferon 51 adefovir 51 Onalta 51 oral proteasome inhibitor 51 secondary hyperparathyroidism 51 Bezielle 51 Ozarelix 51 NY ESO 51 cMET 51 autoimmune inflammatory 51 bacterial conjunctivitis 51 antiviral efficacy 51 Janus kinase 51 registrational 51 Hepatitis B virus HBV 51 tuberculin skin testing 51 severe hypercholesterolemia 51 Xyfid TM 51 VZV 51 Fc fusion protein 51 carcinoid syndrome 51 PLK1 SNALP 51 Herceptin trastuzumab 51 DXL# 51 lamivudine 51 PKC# 51 PEG INTRON R 51 R emtricitabine 51 LNPs 51 velafermin 51 REYATAZ ® 51 Staphylococcus aureus MRSA 51 Glufosfamide 51 KRAS mutations occur 51 Pseudomonas aeruginosa infections 51 rituximab Rituxan 51 PSN# [002] 51 leukemia ALL 51 immunosuppressed patients 51 gastrin analogue TT 51 monoclonal antibody MAb 51 rilonacept 51 oral FTY# 51 Raltegravir 51 cutaneous T cell 51 Debio 51 ribavirin Copegus 51 lucinactant 51 Phase III clinical trials 51 Tipranavir 51 Atripla combines 51 Eculizumab 51 cethromycin 51 AZT zidovudine Retrovir 51 HepaGam B 51 immunotoxin 51 Onco TCS 51 ELND-#/AZD-# 51 elevated triglyceride levels 51 CIMZIA ™ 51 PEGylated 51 diabetic kidney 51 Phenoptin 51 bendamustine 51 Pirfenidone 51 systemic RNA interference 51 Maribavir 51 thrombopoietin 51 log# reduction 51 TNFa 51 CD# CEA 51 non alcoholic steatohepatitis 51 abacavir Ziagen 51 eosinophilic asthma 51 OncoVex 51 HER2 overexpression 51 Azilect ® 51 Pegasys ® 51 Beta catenin pathway 51 Cathepsin S 51 chronic ITP patients 51 B CLL 51 Dacogen injection 51 cancer therapeutics 51 CTLA4 Ig 51 bexarotene 51 Interferon alpha 51 pancreatic insufficiency 51 Isentress raltegravir 51 MLN# 51 VEGF receptor inhibitor 51 Trichomonas vaginalis 51 N. gonorrhoeae 51 cannabinor 51 therapeutic monoclonal antibody 51 VivaGel ™ 51 oncolytic viruses 51 diabetic neuropathic pain 51 Aviptadil 51 skeletal metastases 51 receptor tyrosine kinase inhibitor 51 STELARA ™ 51 Ophena TM 51 CytoFab 51 OncoVEX 51 romiplostim 51 Pruvel 51 oncologic diseases 51 elvucitabine 51 radiation sensitizer 51 biologic DMARD 51 volociximab 51 Phase Ib IIa 51 Allovectin 7 R 51 daclizumab 51 atazanavir sulfate 51 Protexia R 51 Alferon LDO 51 disease CDAD 51 rituximab refractory 51 Vaccine Candidate 51 CMV vaccine 51 micafungin 51 TransVax TM 51 immunotherapeutic vaccine 51 Fludase 51 RSD# oral 51 Pralatrexate 51 lomitapide 51 Combivir Kivexa 51 tenofovir disoproxil fumarate 51 Raptiva ® 51 Therapeutic Vaccine 51 SinuNase ™ 51 simplex virus 51 Hepsera 51 BiTE antibody 51 K ras mutations 51 Exelixis XL# 51 relapsed refractory multiple myeloma 51 seronegative 51 teriflunomide 51 Factor IX 51 Gleevec resistant 51 ISENTRESS 51 include Healive 51 Oritavancin 51 investigational pan BCR 51 Vidaza azacitidine 51 formerly LymphoStat B 51 AKT inhibitor 51 anti TNF alpha 51 Dasatinib 51 protease inhibitor 51 Monoclonal antibody 51 MYCAMINE 51 reslizumab 51 ApoB SNALP 51 non nucleoside 51 small molecule inhibitor 51 chemical entities NCEs 51 personalized cellular immunotherapy 51 hepatitis B infection 51 chronic periodontitis 51 monoclonal antibody therapeutics 51 HIV RNA 51 chemokine receptors 51 thetreatment 51 delafloxacin 51 leukemia APL 51 ritonavir boosted 51 TACI Ig 51 BHT DNA 51 ganciclovir 51 Cytomegalovirus CMV 51 Cytomegalovirus 51 Hereditary angioedema HAE 51 metastatic RCC 51 PEG INTRON 51 Ebola virus infection 51 recurrent NSCLC 51 VEGF Trap 51 SAR# [004] 51 organ transplant rejection 51 virus AAV 51 TRAIL receptor 51 Gleevec imatinib 51 Investigational Treatment 51 visilizumab 51 BEXXAR 51 bacterium Mycobacterium tuberculosis 51 IAP inhibitor 51 Friedreich Ataxia FRDA 51 liposomal formulation 51 castration resistant prostate cancer 51 chemokine receptor 51 SGLT2 51 tenofovir emtricitabine 51 Ustekinumab 51 cytokine Interleukin 51 latent tuberculosis 51 genital ulcers 51 basal cell carcinoma BCC 51 alkylating agent 51 oncology therapeutics 51 HPV# 51 NASDAQ SNTA 51 lamivudine refractory patients 51 Nanobody ® 51 Zarnestra 51 ROTATEQ 51 Aurora kinase 51 Bortezomib 51 Teplizumab 51 antiretroviral naïve 51 BAY #-# 51 GSK # 51 nosocomial pneumonia 51 Salmonella typhi 51 commercializing anti infective 51 AEZS 51 Perifosine 51 Candida infection 51 C5aR 51 Evoltra ® 51 relapsing forms 51 Squalamine 51 XmAb ™ 51 Tolvaptan 51 pancreatic NET 51 JAK2 inhibitor 51 trimethoprim sulfamethoxazole 51 immunomodulatory 51 PROMACTA 51 stage IIIB 51 DOS# 51 Tofacitinib 51 TORISEL 51 equine osteoarthritis 51 p# biomarker 51 SNT-MC#/idebenone 51 H pylori 51 SparVax TM 51 Phase 1b 51 Virulizin R 51 small molecule 51 CD8 responses 51 acute decompensated heart 51 IMC #B 51 dengue viruses 51 Inc. Nasdaq PPHM 51 CBLC# 51 invasive fungal infections 51 nucleoside naive 51 selective kinase inhibitor 51 chronic hepatitis 51 Symphogen 51 Pafuramidine 51 torezolid phosphate 51 antiviral therapeutics 51 topical anti infective 51 latent TB 51 cancer immunotherapies 51 product platforms AZX# 51 THR beta agonist 51 S. aureus colonization 51 boosted protease inhibitor 51 Hodgkin lymphoma HL 51 microbiological eradication 51 HBeAg negative patients 51 chlamydia gonorrhea syphilis 51 refractory prostate cancer 51 Vaccine Adjuvant 51 chronic myelogenous leukemia CML 51 Apaziquone 51 JAK3 51 Allovectin 7 ® 51 Pathway Inhibitor 51 familial amyloidotic polyneuropathy FAP 51 Azedra 51 chemically modified siRNA 51 TASKi2 51 octreotide implant 51 decitabine 51 JAK inhibitors 50 Phase IIb clinical trials 50 JAK2 V#F 50 Noxafil 50 metastatic renal cell 50 PEG SN# 50 chimeric monoclonal antibody 50 immunosuppressive therapies 50 EZN 50 SNT MC# 50 Pyridorin 50 ® emtricitabine 50 maraviroc 50 GATTEX ® 50 genital HSV 50 hematologic disorders 50 trastuzumab Herceptin R 50 Lymphocytic 50 Valortim 50 virologic failure 50 lintuzumab SGN 50 PANVAC VF 50 APTIVUS r 50 microtubule inhibitor 50 MT# MEDI 50 ospemifene 50 Celsentri Selzentry 50 Nasdaq RDEA 50 atazanavir Reyataz 50 antiretroviral naive 50 small molecule activators 50 Nexavar sorafenib 50 PSMA ADC 50 rheumatoid arthritis psoriatic arthritis 50 receptor inhibitor 50 RhuDex R 50 PRTX 50 Mycobacterium tuberculosis 50 Zolinza 50 vilazodone 50 pathophysiological effects 50 attenuated strain 50 hepatitis C. 50 genital ulcer disease 50 rusalatide acetate 50 elinogrel 50 prostone 50 Vesivirus 50 Vandetanib 50 LEXIVA r 50 non metastatic osteosarcoma 50 Veronate 50 sustained virological response 50 Tesmilifene 50 serotype #A 50 seropositive patients 50 S. aureus 50 BiTE R 50 tiapamil 50 atypical hemolytic uremic syndrome 50 NNRTI 50 Lupus nephritis 50 vitreoretinal disorders 50 alpha 2a 50 neovascular diseases 50 MabThera Rituxan 50 PrevOnco 50 congenital ichthyosis 50 Chrysalin 50 chronic lymphocytic leukemia CLL 50 pediatric acute lymphoblastic 50 T#I mutation 50 antisense inhibitors 50 HeFH 50 acne vulgaris 50 NTDDS 50 endophthalmitis